TY - JOUR
T1 - MET/HGF signaling pathway in ovarian carcinoma
T2 - Clinical implications and future direction
AU - Mhawech-Fauceglia, Paulette
AU - Afkhami, Michelle
AU - Pejovic, Tanja
PY - 2012
Y1 - 2012
N2 - The HGF/MET signaling pathway is abnormal in numerous cancers including ovarian cancer. MET is expressed in 70% of human cancer and it is overexpressed in 30% of ovarian cases and cancer cell lines. The HGF/MET pathway plays a role in the initiation and progression of ovarian cancer through the most distinctive biologic program known as "invasive growth" which is accomplished through a coordinated activation of cell motility, invasiveness, degradation of extracellular matrix, survival, and proliferation. Because of its ubiquitous role in cancer, the MET axis seems to be an attractive target for cancer therapy. Numerous HGF/MET pathway inhibitor compounds are already in use in clinical trials in various solid tumors. In this paper, we will discuss the HGF/MET pathway in ovarian cancer, its clinical significance, and its potential use as a target therapy in the future.
AB - The HGF/MET signaling pathway is abnormal in numerous cancers including ovarian cancer. MET is expressed in 70% of human cancer and it is overexpressed in 30% of ovarian cases and cancer cell lines. The HGF/MET pathway plays a role in the initiation and progression of ovarian cancer through the most distinctive biologic program known as "invasive growth" which is accomplished through a coordinated activation of cell motility, invasiveness, degradation of extracellular matrix, survival, and proliferation. Because of its ubiquitous role in cancer, the MET axis seems to be an attractive target for cancer therapy. Numerous HGF/MET pathway inhibitor compounds are already in use in clinical trials in various solid tumors. In this paper, we will discuss the HGF/MET pathway in ovarian cancer, its clinical significance, and its potential use as a target therapy in the future.
UR - http://www.scopus.com/inward/record.url?scp=84872801636&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872801636&partnerID=8YFLogxK
U2 - 10.1155/2012/960327
DO - 10.1155/2012/960327
M3 - Review article
C2 - 23320251
AN - SCOPUS:84872801636
SN - 2042-003X
VL - 2012
JO - Pathology Research International
JF - Pathology Research International
M1 - 960327
ER -